impact factor
logo
 

Biological agents in psoriatic arthritis

 

Interleukin-17 inhibition in psoriatic arthritis


1, 2

 

  1. Western University, London, ON, Canada.
  2. Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy (CIT), University of California, La Jolla, CA, USA. akavanaugh@ucsd.edu

CER8879
2015 Vol.33, N°5 ,Suppl.93
PI 0119, PF 0123
Biological agents in psoriatic arthritis

Free to view
(click on article PDF icon to read the article)

PMID: 26471234 [PubMed]

Received: 20/08/2015
Accepted : 20/08/2015
In Press: 15/10/2015
Published: 16/10/2015

Abstract

Greater understanding of the underlying disease process has led to the development of targeted therapeutic agents and innovative strategies in the treatment of psoriatic arthritis (PsA). This report addresses novel medications targeting the T helper 17 cell pathway, specifically those inhibiting interleukin-17A and its receptor, and discusses their role as effective therapies in the management of PsA.

Rheumatology Article